- Mechanism of action
- Putatively via NMDA receptors and α1-adrenergic receptors, and via interaction with glucocorticoid-induced leucine zipper (GILZ) within the MAPK cascade. It lowers basal corticotropin release and modulates nocturnal N-acetyltransferase activity in the pineal gland.
- Benefits & use
- In animal models, DSIP promotes slow-wave EEG activity (delta sleep) without suppressing REM sleep. It shows stress-protective, anticonvulsant and immunomodulating properties. In a 2021 rat study, DSIP accelerated motor recovery after focal cerebral ischemia.
- Study status
- Several small, partly placebo-controlled human trials (Schneider-Helmert 1981/1987, Monti 1987, Bes 1992) report mixed effects in chronic insomnia. A 2021 rat study (Tukhovskaya et al.) demonstrates improved motor recovery after stroke. No FDA or EMA approval; gene and specific receptor have not yet been identified.
- Dosing note
- Human insomnia studies used 25-50 nmol/kg as a slow intravenous infusion before sleep. This is purely informational from the published literature and not a dosage recommendation. Any use must remain under medical supervision.
DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide with the sequence WAGGDASGE, first isolated in 1974 by the Basel group of Schoenenberger and Monnier from the cerebral venous blood of sleeping rabbits. It is one of the earliest "sleep peptides" in neuroscience and remains of research interest for its delta-sleep-promoting, stress-regulating and neuroprotective actions.
What is DSIP biochemically?
- 9 amino acids, molecular weight ~849 Da
- Very unstable in vitro (half-life ~15 min due to aminopeptidases), likely complexed with carrier proteins in vivo
- Gene, precursor protein and specific receptor have not yet been identified
- Regulated by glucocorticoids and homologous to glucocorticoid-induced leucine zipper (GILZ)
How does DSIP work?
DSIP is thought to act via NMDA receptors and α1-adrenergic receptors, modulating the MAPK cascade. It lowers basal corticotropin release and influences nocturnal N-acetyltransferase activity in the pineal gland - two pathways that couple the sleep-wake rhythm with the stress response.
What effects have been studied?
- Sleep: Induces spindle and delta EEG activity in animal models without suppressing REM phases
- Stress and adaptation: Stress-protective, anticonvulsant and immunomodulating effects in several rodent studies
- Stroke: A 2021 rat study (Tukhovskaya et al.) showed accelerated motor recovery after focal ischemia
- Anaesthesia: Alters BIS index, EEG and heart rate variability as an adjunct to isoflurane (Pomfrett 2009)
What does the human evidence say?
Several small, partly placebo-controlled trials from the 1980s and 90s (Schneider-Helmert, Monti, Bes) have tested DSIP in chronic insomnia. Results are mixed: some patients showed improved sleep continuity, others showed no clear benefit. There is still no FDA or EMA approval for any indication. DSIP remains investigational.
How was DSIP dosed in studies?
Human insomnia studies used 25-50 nmol/kg as a slow intravenous infusion before sleep. This is purely informational from the published literature and not a dosage recommendation. Any use must remain under medical supervision.
How does DSIP fit with other peptides?
DSIP is often mentioned alongside CJC-1295 / Ipamorelin, since both interact with the sleep-wake cycle and nocturnal GH release. More broadly it belongs to the family of neuropeptides such as Selank and Semax, which also address sleep quality and stress regulation.
Key caveats
- No FDA or EMA approval
- Gene and receptor unknown - mechanism partly hypothetical
- Very short plasma half-life - usually administered as infusion in studies
- This article is information, not medical advice and not a recommendation to obtain or use DSIP
Related peptides
Sources
- Tukhovskaya EA et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules 2021 (PMID 34500605)
- Schneider-Helmert D et al. The influence of synthetic DSIP on disturbed human sleep. Experientia 1981 (PMID 7028502)
- Schneider-Helmert D. Effects of DSIP on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol 1987 (PMID 3622582)
- Bes F et al. Effects of DSIP on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992 (PMID 1299794)
- Pomfrett CJ et al. DSIP alters bispectral index, the EEG and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol 2009 (PMID 19142086)